EMEA-003302-PIP01-22-M01 - paediatric investigation plan
gefurulimab
PIPHuman
Key facts
- Active Substance
- gefurulimab
- Therapeutic area
- Nervous system disorders
- Decision number
- P/0249/2024
- PIP number
- EMEA-003302-PIP01-22-M01
- Pharmaceutical form(s)
- Solution for injection
- Condition(s) / indication(s)
- Treatment of myasthenia gravis
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com
Tel: +33 147100615- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date